Tag: CKM
-
The GLP-1 / incretin landscape — why the question moved from “how much weight?” to “what does it change?”
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The incretin (GLP-1) class is expanding beyond glucose and weight into cardiovascular, kidney and heart-failure indications. In the only two head-to-head trials, the dual agent (tirzepatide)…
-
The asymmetry in the US cardiovascular-kidney-metabolic standard — widen the diagnosis, narrow the drug threshold
Evidence-first notes on bioscience and medical affairs, at the edge of the clinic and the market. Information only — not investment advice, not medical advice. The 30-second version What. The four US “definition-setting” societies (AHA, ACC, ADA, ASN) have converged on a single Cardiovascular-Kidney-Metabolic (CKM) syndrome frame that ties heart, kidney and metabolism together, and…
-
Who names the disease — America’s CKM and Europe’s SMD, two axes of definitional power over metabolic disease
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Two upper-level disease taxonomies are competing over the cardio-renal-metabolic continuum. In the United States, the AHA-led CKM (Cardiovascular-Kidney-Metabolic) Syndrome (2023 advisory → 2026 multisociety guideline).…
Uthando Nethemba 